Boston Scientific earns Canadian approval for Taxus

Interventional device developer Boston Scientific has received approval in Canada for its paclitaxel-eluting coronary stent system, the Natick, MA-based company said.

Taxus Liberté is already approved for sale in Europe and other international markets, and is awaiting regulatory approval by the U.S. Food and Drug Administration. Boston Scientific expects to begin marketing the device in Canada immediately.

Related Reading

Boston Scientific to buy CryoCor, April 16, 2008

Boston Scientific inks deal with Surgi-Vision, April 15, 2008

Boston Scientific loses patent suit, February 13, 2008

Cordis wins heart stent patent appeal, January 11, 2008

Boston Scientific sells two more units, January 7, 2008

Copyright © 2008

Page 1 of 180
Next Page